Researchers observed increased real-world incidence of cardiomyopathy in patients treated with trabectedin compared with that seen in the phase 3 study of the drug.
Australian researchers identified the gene using whole-genome sequencing in patients enrolled in the International Sarcoma Kindred Study.
But, there was no difference in DFS, DMFS, or OS between the 2 treatment subtypes at 5 years following the conclusion of the original study.
Study Adds More Evidence to Support Active Surveillance as the Standard of Care for Certain Desmoid Tumors
Experts embrace the "less is more" approach to guide treatment decisions in primary sporadic desmoid tumors.
The switch from a continuous to an intermittent dosing schedule appeared to cut the occurrence of thrombocytopenia in half.
A subset of patients experienced sustained clinical benefit and at least some objective tumor response.
Researchers suggested the use of comparative oncology to identify novel therapies that could have clinical applications in osteosarcoma.
Analysis of transcriptomic data revealed that a subset of patients with these smooth muscle sarcomas have ALK fusions that retain targetable ALK kinase domains.
Patients with fascia-infiltrating sarcoma appeared to have worse survival that those who had either strict superficial or deep soft tissue sarcomas.
The patients who did respond following the eradication of infection, however, had responses up to 1 year.
There were no previously unknown AML-specific mutations or structural variations in immune-related genes among patients with AML who had undergone transplant.
Durvalumab with or without tremelimumab deemed safe and effective in patients with recurrent or metastatic head and neck squamous cell carcinoma.
A prototype intervention increased adherence to tyrosine kinase inhibitor therapy in some patients with chronic myeloid leukemia.
One-view digital breast tomosynthesis with a reduced compression force detected breast cancer with higher sensitivity and lower specificity than 2-view digital mammography.
A clinical trial found a potential marker to identify the patients with advanced esophageal squamous cell carcinoma who were most likely to respond to nivolumab.
Brain metastases were HER2-positive in nearly one-third of patients with gastrointestinal primary malignancies, suggesting molecular testing may be prudent.
Participant characteristics were similar between surgical treatment groups.
Patient-reported quality measures, collected from those who underwent surgery for GI cancer, offered clinicians valuable insight into care management.
In patients who developed CRC, those who had familial CRC type X were found to have worse survival outcomes than those who had Lynch syndrome.
A systematic review and meta-analysis determined that carriers for a mutation to BRCA1, but not BRCA2, have an increased risk of colorectal cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Moving Targets: Off-Label Prescribing of Targeted Therapies
- New Algorithm Improves Outcome Prediction for Diffuse Large B-Cell Lymphoma
- 2-Year TKI Consolidation Allowed for TKI Cessation in Select Patients With CML
- Trial Identifies Marker for Response to Immunotherapy in Esophageal Cancer
- Immunotherapy Combo in Head and Neck Cancer Shows Activity in Phase 2 Trial
- Study Finds Real-World Data on Cardiac Toxicity of Trabectedin May Be Limited
- POT1 Revealed as a Sarcoma Predisposition Gene
- IMRT Linked to Fewer Instances of Local Recurrence in Sarcoma: A Long-Term Follow-Up
- Study Adds More Evidence to Support Active Surveillance as the Standard of Care for Certain Desmoid Tumors
- Palliative Care and Survivorship